Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Indaptus Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +3 vs. Q3 2023
- Shares held
- 602.3K
- +31.7K (+5.6%) vs. Q3 2023
- Total value
- $1.06M
- −$510.1K (−32.5%) vs. Q3 2023
- New holders
- 3
- 6 more added
- Sold out
- 0
- 2 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INDP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $1.15M |
| Q1 2026 | 6 | $128.5K |
| Q4 2025 | 4 | $93.7K |
| Q3 2025 | 5 | $57.9K |
| Q2 2025 | 5 | $3.23K |
| Q1 2025 | 19 | $377.8K |
| Q4 2024 | 20 | $539.6K |
| Q3 2024 | 18 | $750.2K |
| Q2 2024 | 21 | $1.26M |
| Q1 2024 | 17 | $1.31M |
| Q4 2023 | 19 | $1.06M |
| Q3 2023 | 16 | $1.57M |
| Q2 2023 | 15 | $1.11M |
| Q1 2023 | 15 | $1.08M |
| Q4 2022 | 18 | $838.5K |
| Q3 2022 | 18 | $1.22M |
| Q2 2022 | 17 | $1.31M |
| Q1 2022 | 17 | $6.81M |
| Q4 2021 | 15 | $10.5M |
| Q3 2021 | 15 | $4.24M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Indaptus Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 256,265 | $451.0K | 0.00% | +5,517+2.2% | Added |
| Investment House LLC | 102,437 | $180.3K | 0.01% | −412−0.4% | Reduced |
| Geode Capital Management, LLC | 54,767 | $97.0K | 0.00% | 00.0% | Unchanged |
| Strategy Asset Managers LLC | 45,336 | $79.8K | 0.02% | 00.0% | Unchanged |
| Pine Valley Investments Ltd Liability Co | 44,240 | $77.9K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 29,400 | $52.0K | 0.00% | +5,000+20.5% | Added |
| Vivaldi Capital Management, LLC | 24,000 | $40.0K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 19,473 | $34.5K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 16,518 | $29.2K | 0.00% | +16,518 | New |
| Tower Research Capital LLC (TRC) | 4,696 | $8.27K | 0.00% | +1,663+54.8% | Added |
| UBS Group AG | 3,699 | $6.51K | 0.00% | +3,562+2,600.0% | Added |
| Morgan Stanley | 884 | $1.55K | 0.00% | −145−14.1% | Reduced |
| Bangor Savings Bank | 400 | $704 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 104 | $183 | 0.00% | +2+2.0% | Added |
| JPMorgan Chase & Co | 9 | $16 | 0.00% | +2+28.6% | Added |
| Group One Trading, L.P. | 7 | $12 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 3 | $5 | 0.00% | +3 | New |
| Qube Research & Technologies Ltd | 1 | $2 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 38 | $0 | 0.00% | +38 | New |